What is The Effectiveness of Intravenous Magnesium Supplementation Compared to Standard Care on Clinical Outcomes in Critically Ill Patients with Hypomagnesemia? : A Systematic Review
Abstract
Introduction: Hypomagnesemia is common in critically ill patients and is associated with adverse outcomes. However, the effectiveness of intravenous (IV) magnesium supplementation remains controversial.
Methods: This systematic review screened 80 studies including RCTs, etc across general ICUs, cardiac surgery, sepsis, neurological conditions, and other critical illnesses. Outcomes assessed included mortality, arrhythmias, neurological recovery, length of stay, and adverse events.
Results: In post-cardiac surgery, IV magnesium significantly reduced supraventricular arrhythmias (RR 0.77; 95% CI: 0.63–0.93) and ventricular arrhythmias (RR 0.52; 95% CI: 0.31–0.87) [1,2]. In sepsis, magnesium improved lactate clearance and reduced ICU stay from 15 to 8 days (p<0.01) [3], with a network meta-analysis showing reduced short-term mortality (RR 0.33; 95% CI: 0.14–0.79) [4]. In AKI on CRRT, magnesium was associated with significantly lower 90-day mortality (aHR 0.38; 95% CI: 0.18–0.83) [5]. In aneurysmal SAH, magnesium reduced vasospasm (OR 0.61; 95% CI: 0.37–0.99) and delayed cerebral ischemia (OR 0.57; 95% CI: 0.37–0.88) but did not improve overall neurological outcome [6,7]. In TBI, the largest RCT showed no benefit and potential harm [8]. In general ICU patients with borderline hypomagnesemia, routine supplementation did not improve 24-hour clinical outcomes [9]. Extended infusion strategies improved magnesium retention compared to rapid boluses [11,12]. Adverse events were…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.